Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience
dc.contributor.author | Ugurluer, Gamze | |
dc.contributor.author | Mustafayev, Teuta Zoto | |
dc.contributor.author | Gungor, Gorkem | |
dc.contributor.author | Atalar, Banu | |
dc.contributor.author | Abacioglu, Ufuk | |
dc.contributor.author | Sengoz, Meric | |
dc.contributor.author | Agaoglu, Fulya | |
dc.contributor.author | Demir, Gokhan | |
dc.contributor.author | Ozyar, Enis | |
dc.date.accessioned | 2023-02-21T12:32:22Z | |
dc.date.available | 2023-02-21T12:32:22Z | |
dc.date.issued | 2021-01-01 | |
dc.description.abstract | Purpose: We aimed to present our initial clinical experience on the implementation of a stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic disease. Materials and Methods: Twenty-one patients (24 lesions) with liver metastasis treated with SMART were included in this retrospective study. Step-and-shoot intensity-modulated radiotherapy technique was used with daily plan adaptation. During delivery, real-time imaging was used by acquiring planar magnetic resonance images in sagittal plane for monitoring and gating. Acute and late toxicities were recorded both during treatment and follow-up visits. Results: The median follow-up time was 11.6 months (range, 2.2 to 24.6 months). The median delivered total dose was 50 Gy (range, 40 to 60 Gy) | |
dc.description.abstract | with a median fraction number of 5 (range, 3 to 8 fractions) and the median fraction dose was 10 Gy (range, 7.5 to 18 Gy). Ninety-three fractions (83.7\%) among 111 fractions were re-optimized. No patients were lost to follow-up and all patients were alive except one at the time of analysis. All of the patients had either complete (80.9\%) or partial (19.1\%) response at irradiated sites. Estimated 1-year overall survival was 93.3\%. Intrahepatic and extrahepatic progression-free survival was 89.7\% and 73.5\% at 1 year, respectively. There was no grade 3 or higher acute or late toxicities experienced during the treatment and follow-up course. Conclusion: SMART represents a new, noninvasive and effective alternative to current ablative radiotherapy methods for treatment of liver metastases in oligometastatic disease with the advantages of better visualization of soft tissue, real-time tumor tracking and potentially reduced toxicity to organs at risk. | |
dc.description.issue | 1 | |
dc.description.issue | MAR | |
dc.description.pages | 33-40 | |
dc.description.volume | 39 | |
dc.identifier.doi | 10.3857/roj.2020.00976 | |
dc.identifier.uri | https://hdl.handle.net/11443/1020 | |
dc.identifier.uri | http://dx.doi.org/10.3857/roj.2020.00976 | |
dc.identifier.wos | WOS:000636461800005 | |
dc.publisher | KOREAN SOC THERAPEUTIC RADIOLOGY \& ONCOLOGY | |
dc.relation.ispartof | RADIATION ONCOLOGY JOURNAL | |
dc.subject | Liver | |
dc.subject | Metastases | |
dc.subject | Oligometastatic disease | |
dc.subject | Stereotactic radiation therapy | |
dc.subject | MRI | |
dc.subject | Image guidance | |
dc.title | Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience | |
dc.type | Article |